QQQ   389.56 (-0.16%)
AAPL   189.24 (-0.61%)
MSFT   378.61 (-1.07%)
META   331.98 (-2.07%)
GOOGL   134.91 (-1.67%)
AMZN   146.20 (-0.56%)
TSLA   244.05 (-1.08%)
NVDA   482.05 (+0.80%)
NIO   7.19 (-0.28%)
BABA   74.77 (-2.57%)
AMD   123.73 (+1.41%)
T   16.30 (+0.74%)
F   10.61 (+2.31%)
MU   76.55 (+0.56%)
CGC   0.56 (+3.61%)
GE   118.91 (+0.05%)
DIS   92.45 (-0.05%)
AMC   7.17 (+7.01%)
PFE   30.08 (+1.31%)
PYPL   57.97 (-0.86%)
XOM   102.27 (-1.57%)
QQQ   389.56 (-0.16%)
AAPL   189.24 (-0.61%)
MSFT   378.61 (-1.07%)
META   331.98 (-2.07%)
GOOGL   134.91 (-1.67%)
AMZN   146.20 (-0.56%)
TSLA   244.05 (-1.08%)
NVDA   482.05 (+0.80%)
NIO   7.19 (-0.28%)
BABA   74.77 (-2.57%)
AMD   123.73 (+1.41%)
T   16.30 (+0.74%)
F   10.61 (+2.31%)
MU   76.55 (+0.56%)
CGC   0.56 (+3.61%)
GE   118.91 (+0.05%)
DIS   92.45 (-0.05%)
AMC   7.17 (+7.01%)
PFE   30.08 (+1.31%)
PYPL   57.97 (-0.86%)
XOM   102.27 (-1.57%)
QQQ   389.56 (-0.16%)
AAPL   189.24 (-0.61%)
MSFT   378.61 (-1.07%)
META   331.98 (-2.07%)
GOOGL   134.91 (-1.67%)
AMZN   146.20 (-0.56%)
TSLA   244.05 (-1.08%)
NVDA   482.05 (+0.80%)
NIO   7.19 (-0.28%)
BABA   74.77 (-2.57%)
AMD   123.73 (+1.41%)
T   16.30 (+0.74%)
F   10.61 (+2.31%)
MU   76.55 (+0.56%)
CGC   0.56 (+3.61%)
GE   118.91 (+0.05%)
DIS   92.45 (-0.05%)
AMC   7.17 (+7.01%)
PFE   30.08 (+1.31%)
PYPL   57.97 (-0.86%)
XOM   102.27 (-1.57%)
QQQ   389.56 (-0.16%)
AAPL   189.24 (-0.61%)
MSFT   378.61 (-1.07%)
META   331.98 (-2.07%)
GOOGL   134.91 (-1.67%)
AMZN   146.20 (-0.56%)
TSLA   244.05 (-1.08%)
NVDA   482.05 (+0.80%)
NIO   7.19 (-0.28%)
BABA   74.77 (-2.57%)
AMD   123.73 (+1.41%)
T   16.30 (+0.74%)
F   10.61 (+2.31%)
MU   76.55 (+0.56%)
CGC   0.56 (+3.61%)
GE   118.91 (+0.05%)
DIS   92.45 (-0.05%)
AMC   7.17 (+7.01%)
PFE   30.08 (+1.31%)
PYPL   57.97 (-0.86%)
XOM   102.27 (-1.57%)

Daiichi Sankyo Stock Price, News & Analysis (OTCMKTS:DSNKY)

$26.93
-0.08 (-0.30%)
(As of 11/28/2023 ET)
Compare
Today's Range
$26.63
▼
$27.10
50-Day Range
$23.74
▼
$29.03
52-Week Range
$23.72
▼
$37.57
Volume
152,370 shs
Average Volume
146,625 shs
Market Capitalization
N/A
P/E Ratio
0.23
Dividend Yield
83.43%
Price Target
N/A
Stock AnalysisAnalyst ForecastsChartHeadlinesShort Interest

Daiichi Sankyo MarketRank™ Stock Analysis

Analyst Rating
N/A
Upside/​Downside
N/A
Short Interest
Healthy
Dividend Strength
Weak
Based on Four Factors
Sustainability
N/A
News Sentiment
0.93mentions of Daiichi Sankyo in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
N/A

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.82 out of 5 stars

See Top Rated MarketRank™ Stocks Here

DSNKY stock logo

About Daiichi Sankyo Stock (OTCMKTS:DSNKY)

Daiichi Sankyo Company, Limited manufactures, markets, and sells pharmaceutical products worldwide. The company offers Enhertu, a HER2 directed antibody drug conjugate; Turalio, a CSF-1R inhibitor; Vanflyta, a FLT3 inhibitor for the treatment of adult patients with relapsed/refractory FLT3-ITD acute myeloid leukemia; ferric carboxymaltose injection for treating anaemia; and Injectafer for the treatment for iron deficiency anaemia. It also provides olmesartan medoxomil antihypertensive agents; NILEMDO, an oral treatment to help in lowering cholesterol; and Nustendi, a fixed-dose combination tablet of bempedoic acid and ezetimibe for reducing cholesterol. In addition, the company offers Canalia for the treatment of type 2 diabetes mellitus; Emgalty for the treatment of migraine attacks; Pralia for the treatment of anti-osteoporosis/inhibitor of the progression of bone erosion associated with rheumatoid arthritis; Ranmark for the treatment of bone complications caused by bone metastasis from tumors; Tarlige for treating pain; Tenelia for the treatment of Type 2 diabetes mellitus; Venofer for the treatment of iron deficiency anemia; and Vimpat, an anti-epileptic agent. Further, it provides vaccines for influenza, measles/rubella infection, and mumps. The company has a development and commercialization agreement with Merck to jointly develop and commercialize Daiichi Sankyo's DXd antibody drug conjugate (ADC) candidates The company was founded in 1899 and is headquartered in Tokyo, Japan.

DSNKY Stock Price History

DSNKY Stock News Headlines

November 27, 2023 | finance.yahoo.com
Japan panel recommends approval of updated Daiichi Sankyo COVID shot- Kyodo
November 21, 2023 | americanbankingnews.com
Daiichi Sankyo (OTCMKTS:DSNKY) and Gilead Sciences (NASDAQ:GILD) Head to Head Analysis
November 29, 2023 | Autonomix (Ad)
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity
Autonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com
October 31, 2023 | investing.com
Daiichi Sankyo Co., Ltd. (4568)
October 31, 2023 | finance.yahoo.com
Merck Just Made a Big Move -- but Will It Be Enough for Investors Right Now?
October 26, 2023 | finance.yahoo.com
Merck (MRK) Q3 Earnings Top Estimates, COVID Drug Boosts Sales
October 26, 2023 | finance.yahoo.com
‘Guided Missile Drugs’ Could Be Big Pharma’s Secret Weapon
October 23, 2023 | bloomberg.com
Merck Discontinues Developing Drug Candidates With Sichuan Kelun After Daiichi Sankyo Deal
November 29, 2023 | Autonomix (Ad)
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity
Autonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com
October 22, 2023 | finance.yahoo.com
Raludotatug Deruxtecan Continues to Demonstrate Promising Clinical Activity in Patients with Advanced Ovarian Cancer in Early Trial
October 20, 2023 | finance.yahoo.com
Nikkei Falls 0.5%, Dragged by Electronics, Retail Stocks
October 20, 2023 | barrons.com
Japan's Daiichi Sankyo, Merck Announce $22bn Cancer Drug Deal
October 20, 2023 | news.yahoo.com
Merck teams up with Daiichi Sankyo on antibody drug conjugate collaboration
October 20, 2023 | reuters.com
Merck signs $5.5 bln deal with Daiichi for cancer therapy development
October 18, 2023 | finance.yahoo.com
Experimental Drug Wards Off Both Lung and Breast Cancer Progression in Trials
October 16, 2023 | finance.yahoo.com
Daiichi Sankyo Showcases Progress in Developing New Standards of Care for Patients with Industry-Leading DXd ADC Portfolio Across Multiple Cancers at ESMO
September 26, 2023 | finance.yahoo.com
Nikkei Falls 1.1%, Dragged by Pharma, Electronics Stocks
September 25, 2023 | finance.yahoo.com
U.S. Stocks Open Lower After S&P 500 Logs Three Straight Weeks Of Losses
September 25, 2023 | finance.yahoo.com
Daiichi Sankyo Leads Japan Pharma Stocks Higher on Cancer Drug
September 25, 2023 | finance.yahoo.com
Stock Market Today: Bond Yields Climb Toward 4.5%
September 24, 2023 | finance.yahoo.com
Nikkei Flat, Supported by Electronics, Pharma Stocks
September 22, 2023 | finance.yahoo.com
Datopotamab Deruxtecan Demonstrated Statistically Significant and Clinically Meaningful Progression-Free Survival Benefit in Patients with HR Positive, HER2 Low or Negative Breast Cancer in TROPION-Breast01 Phase 3 Trial
September 22, 2023 | finance.yahoo.com
AstraZeneca Surges To 50-Day Line After Breast Cancer Drug Tops Chemo
September 15, 2023 | lse.co.uk
AstraZeneca and Daiichi Sankyo's Enhertu recommended for approval
September 15, 2023 | finance.yahoo.com
UPDATE 1-EU regulator backs AstraZeneca and Daiichi's lung cancer drug
September 12, 2023 | bloomberg.com
Daiichi to File for US Approval of New Lung Cancer Drug by March
September 10, 2023 | finance.yahoo.com
Patritumab Deruxtecan Demonstrated Clinically Meaningful and Durable Responses in Patients with EGFR-Mutated Metastatic Non-Small Cell Lung Cancer in HERTHENA-Lung01 Phase 2 Trial
See More Headlines
Receive DSNKY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Daiichi Sankyo and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange
OTCMKTS
Industry
Drug Manufacturers - General
Sub-Industry
N/A
Sector
Medical
Current Symbol
OTCMKTS:DSNKY
CUSIP
N/A
CIK
N/A
Web
www.daiichisankyo.com
Phone
(136) 225-1111
Fax
N/A
Employees
17,435
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
N/A
Trailing P/E Ratio
0.23
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
N/A
Quick Ratio
N/A

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
N/A
Price / Book
N/A

Miscellaneous

Outstanding Shares
N/A
Free Float
N/A
Market Cap
N/A
Optionable
Not Optionable
Beta
N/A
12 Stocks Corporate Insiders are Abandoning Cover
12 Stocks Corporate Insiders are Abandoning

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

Key Executives

  • Mr. Sunao Manabe D.V.M. (Age 69)
    Ph.D., Group CEO & Executive Chairperson
    Comp: $1.87M
  • Mr. Hiroyuki Okuzawa (Age 61)
    President, COO & Representative Director
    Comp: $735.57k
  • Mr. Masahiko Ohtsuki (Age 64)
    Senior Managing Exec. Officer, Head of Global DX, Chief Digital Transformation Officer & Director
    Comp: $735.57k
  • Dr. Shoji Hirashima (Age 62)
    Senior Managing Executive Officer, Head of Japan Business Unit & Representative Director
    Comp: $795.75k
  • Mr. Koji Ogawa
    Managing Executive Officer, Head of Global Corporate Planning & Management and CFO
  • Hiroto Kashiwase
    Managing Executive Officer, Head of Technology Management HQ and Head of Supply Chain HQ
  • Naoto Tsukaguchi
    Gen. Counsel, Corp. Officer, Head of Global Leg., IP, Global Compl. and Risk & VP of Leg. Aff. Dept.
  • Kentaro Asakura
    Vice President of Corporate Communications Department
  • Ms. Marielle Cohard-Radice M.D.
    Global Head of Development
  • Akio Sakurai
    Corporate Officer, Head of Sales and Marketing Div. & Japan Business Unit

Key Competitors

View All Competitors














DSNKY Stock Analysis - Frequently Asked Questions

Should I buy or sell Daiichi Sankyo stock right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Daiichi Sankyo in the last twelve months. There are currently 1 sell rating and 1 hold rating for the stock. The consensus among Wall Street research analysts is that investors should "reduce" DSNKY shares.
View DSNKY analyst ratings or view top-rated stocks.

How have DSNKY shares performed in 2023?

Daiichi Sankyo's stock was trading at $32.19 at the beginning of 2023. Since then, DSNKY stock has decreased by 16.3% and is now trading at $26.93.
View the best growth stocks for 2023 here.

Are investors shorting Daiichi Sankyo?

Daiichi Sankyo saw a decrease in short interest in November. As of November 15th, there was short interest totaling 35,500 shares, a decrease of 30.8% from the October 31st total of 51,300 shares. Based on an average daily volume of 166,300 shares, the days-to-cover ratio is presently 0.2 days.
View Daiichi Sankyo's Short Interest.

Is Daiichi Sankyo a good dividend stock?

Daiichi Sankyo (OTCMKTS:DSNKY) pays an annual dividend of $22.47 per share and currently has a dividend yield of 3.12%. The dividend payout ratio is 19.59%. This payout ratio is at a healthy, sustainable level, below 75%.

How do I buy shares of Daiichi Sankyo?

Shares of DSNKY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (OTCMKTS:DSNKY) was last updated on 11/29/2023 by MarketBeat.com Staff

My Account -